2001
Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP‐treated monkeys: Feasibility relevant to multiple‐target grafting as a therapy for Parkinson's disease
Collier TJ, Sortwell CE, Elsworth JD, Taylor JR, Roth RH, Sladek JR, Redmond DE. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP‐treated monkeys: Feasibility relevant to multiple‐target grafting as a therapy for Parkinson's disease. The Journal Of Comparative Neurology 2001, 442: 320-330. PMID: 11793337, DOI: 10.1002/cne.10108.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAxonsBrain Tissue TransplantationCell DifferentiationChlorocebus aethiopsDopamineGraft SurvivalHomovanillic AcidImmunohistochemistryMaleNeostriatumNerve RegenerationNeuritesNeuronsParkinsonian DisordersRecovery of FunctionStem Cell TransplantationStem CellsSubstantia NigraTreatment OutcomeTyrosine 3-MonooxygenaseConceptsSubstantia nigraParkinson's diseaseDA neuronsVentral mesencephalonTyrosine hydroxylaseTH-positive fiber densityEmbryonic DA neuronsEmbryonic dopamine neuronsRostral substantia nigraStriatal DA depletionVentral mesencephalic graftsBasal ganglia circuitryBasal ganglia structuresSuboptimal therapeutic outcomesAfrican green monkeysDA modulationGrafted neuronsVM graftsMesencephalic graftsParkinsonian monkeysSN neuronsDA depletionReplacement therapyDA replacementDA levels
1999
Chapter 12 Fetal Grafts in Parkinson's Disease Primate Models
Sladek J, Collier T, Elsworth J, Roth R, Taylor J, Redmond D. Chapter 12 Fetal Grafts in Parkinson's Disease Primate Models. 1999, 321-364. DOI: 10.1016/b978-012705070-6/50013-5.Peer-Reviewed Original ResearchDisease patientsFetal tissue graftsParkinson's disease patientsProgressive neurological disorderEntire striatumParkinsonian symptomsFetal graftsClinical benefitDopaminergic neuronsSubstantia nigraClinical trialsNeurosurgical interventionPrimate modelParkinson's diseaseTissue graftDonor tissueNeurological disordersSource of cellsNeurodegenerative disordersFunctional changesProgressive lossHuman embryonic tissuesOptimal ageGraftSingle donor
1998
In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector
During M, Samulski R, Elsworth J, Kaplitt M, Leone P, Xiao X, Li J, Freese A, Taylor J, Roth R, Sladek J, O’Malley K, Redmond D. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Therapy 1998, 5: 820-827. PMID: 9747462, DOI: 10.1038/sj.gt.3300650.Peer-Reviewed Original ResearchMeSH Keywords1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAromatic-L-Amino-Acid DecarboxylasesChlorocebus aethiopsDependovirusDopamineDopamine AgentsGene ExpressionGene Transfer TechniquesGenetic VectorsHumansImmunohistochemistryMaleParkinson DiseaseTrigeminal Caudal NucleusTyrosine 3-MonooxygenaseConceptsTyrosine hydroxylaseStriatal cellsDopamine-depleted monkeysAdeno-associated virus vectorProduction of dopamineParkinsonian monkeysTransient feverSevere hyperactivityStriatal dopaminePrimate neuronsStereotactic injectionHistological evidencePrimate modelInjection tractNeurotoxin MPTPDopamine productionParkinson's diseaseTreatment groupsSignificant toxicityBehavioral effectsVivo gene therapyElevated levelsBiochemical effectsFirst dayMonkeys
1997
Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)
Taylor J, Elsworth J, Roth R, Sladek J, Redmond D. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 1997, 81: 745-755. PMID: 9316026, DOI: 10.1016/s0306-4522(97)00214-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseSevere parkinsonismAdult male African green monkeysMale African green monkeysTetrahydropyridine-induced parkinsonismMPTP-induced parkinsonismIdiopathic Parkinson's diseaseNovel therapeutic treatmentsLong-term deficitsAfrican green monkeysGroups of animalsNon-human primatesMPTP treatmentParkinsonian monkeysMPTP administrationVervet monkeysFunctional deficitsInitial severityStable parkinsonismBehavioral deficitsAnimal modelsParkinsonismParkinsonian subjectsMPTPTherapeutic treatment
1993
Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Futurea
REDMOND D, ROTH R, SPENCER D, NAFTOLIN F, LERANTH C, ROBBINS R, MAREK K, ELSWORTH J, SASS K, TAYLOR J, SLADEK J. Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Futurea. Annals Of The New York Academy Of Sciences 1993, 695: 258-266. PMID: 8239293, DOI: 10.1111/j.1749-6632.1993.tb23064.x.Peer-Reviewed Original ResearchConceptsNeural transplantationParkinson's diseaseDopamine neuronsCellular replacementClinical treatmentFetal cellsNeural tissue transplantsNeural tissueIdiopathic Parkinson's diseaseDopamine-producing cellsFunctional effectsBest medical treatmentFetal neural tissueImportant functional effectsHuman neural tissueEssential neuromodulatorDrug therapyIdiopathic diseaseClinical conditionsTherapeutic experimentsBrain cellsIneffective treatmentMedical treatmentTissue transplantsTransplantation
1991
Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls
Taylor J, Elsworth J, Roth R, Sladek J, Collier T, Redmond D. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls. Experimental Brain Research 1991, 85: 335-348. PMID: 1893983, DOI: 10.1007/bf00229411.Peer-Reviewed Original ResearchConceptsCaudate nucleusBehavioral deficitsHealthy behaviorsFetal substantia nigra cellsFetal substantia nigraIdiopathic Parkinson's diseasePoverty of movementType of graftDays/weekSubstantia nigra cellsTime of sacrificePre-treatment levelsSN cellsSpecific behavioral effectsMPTP treatmentMPTP toxicityParkinsonian signsSubstantia nigraControl subjectsInitiation of movementBrain sitesLimb tremorParkinson's diseaseControl animalsMPTPThe D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys
Lawrence M, Redmond D, Elsworth J, Taylor J, Roth R. The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys. Life Sciences 1991, 49: pl229-pl234. PMID: 1836030, DOI: 10.1016/0024-3205(91)90299-q.Peer-Reviewed Original ResearchConceptsSCH 23390African green monkeysD1 antagonistHealthy African green monkeysGreen monkeysParkinsonian side effectsD1 receptor antagonistPoverty of movementSigns of parkinsonismSelective D1 antagonistFull D1 agonistParkinsonian signsReceptor antagonistD1 agonistD1 receptorsSystemic administrationParkinson's diseasePsychiatric disordersSide effectsMotor changesClinical useParkinsonismAntagonistBlink rateMonkeys
1989
Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions
Elsworth J, Deutch A, Redmond D, Taylor J, Sladek J, Roth R. Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions. Neuroscience 1989, 33: 323-331. PMID: 2622529, DOI: 10.1016/0306-4522(89)90212-1.Peer-Reviewed Original ResearchConceptsHomovanillic acid concentrationsParkinson's diseaseStriatal regionsHomovanillic acid/dopamine ratioGross motor abnormalitiesDepletion of dopamineHomovanillic acid levelsLoss of dopamineIdiopathic Parkinson's diseaseCaudate nucleus dopamineAsymptomatic monkeysTetrahydropyridine (MPTP) treatmentAsymptomatic groupSymptomatic groupDopamine lossTetrahydropyridine (MPTP) toxicityMotor abnormalitiesDopamine ratioCaudate nucleusSignificant negative correlationVentromedial regionStriatum